ArticleNagoya journal of medical science2026
Effect of neurotrophin-3 on bone healing in distraction osteogenesis.
Article in Nagoya journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Distraction osteogenesis (DO) is a surgical technique used to repair skeletal defects by promoting bone and soft tissue regeneration. However, prolonged use of external fixators often causes complications such as infections and joint contractures. Neurotrophin-3 (NT-3) enhances osteoblast differentiation via bone morphogenetic protein-2 (BMP-2) and Akt signaling and may also modulate the Wnt/β-catenin pathway. In this study, we investigated the role of NT-3 in bone regeneration during DO. A DO model was established in 9-week-old male ICR mice, in which tibiae were osteotomized and stabilized with external fixators under anesthesia. After a 5-day latency period, distraction was performed at 0.2 mm every 12 hours for 8 days. RNA was extracted at defined time points post-osteotomy for quantitative polymerase chain reaction (qPCR) analysis, and NT-3 was administered post-distraction. Bone regeneration was evaluated by radiographic, histological, and biomechanical analyses. The effects of NT-3 and Dickkopf-1 were further examined in ST2 bone marrow-derived mesenchymal stem cells. NT-3 significantly enhanced bone formation, increased bone mineral density within the DO gap, and improved the mechanical stiffness of regenerated bone. Histological examination revealed earlier bone continuity and greater callus formation in the NT-3 group. Gene expression analysis demonstrated upregulation of Wnt/β-catenin pathway components, including Wnt10b, β-catenin, and low-density lipoprotein receptor-related protein 5 (LRP5). In ST2 cells, NT3 increased the expression of LRP5, LRP6, β-catenin, and Runx2, while cotreatment with Dickkopf1 abolished these effects. These findings suggest that NT-3 promotes bone regeneration during DO by activating the Wnt/β-catenin signaling pathway, highlighting its therapeutic potential to improve DO outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.